Skip to main navigation

Skip to content

Careers
Contact Us

Home
About
Research & Development
Therapies
Newsroom
Investors

Careers
Contact Us

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Sep 15, 2026

Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Sep 10, 2026

Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting

Aug 11, 2026

Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights

Jul 28, 2026

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

Jul 27, 2026

Legend Biotech Announces CEO Transition

Jun 17, 2026

Legend Biotech Corporation Announces Pricing of Public Offering

Jun 17, 2026

Legend Biotech Corporation Announces Proposed Public Offering

Jun 14, 2026

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Jun 02, 2026

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Jun 01, 2026

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 18

GLOBAL HEADQUARTERS

77 Corporate Drive, 4th Floor

Bridgewater, NJ 08807

+1-732-515-4652

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY NOTICE
LEGAL NOTICE
CONTACT US
SITE MAP

© 2026 Legend Biotech. All rights reserved. dedication

You are about to leave Investors.LegendBiotech.com